Republican Congressman, Jeff Duncan is urging the US FDA to hold a public hearing to address their decision that beta-nicotinamide mononucleotide (NMN) does not qualify as a dietary ingredient. In a letter addressed to the FDA, Duncan poses a series of queries, including whether the agency has been in communication with major e-commerce platforms such as Amazon, that has implemented limitations on the sale of NMN. Duncan has set a deadline of 11 May, 2023 for the FDA to provide a response to his inquiries.
Duncan’s request for a public hearing stems from the FDA’s classification of NMN as ineligible for dietary ingredient status. By seeking clarification, Duncan hopes to shed light on the reasoning behind this decision and gather information about the FDA’s interactions with prominent e-commerce platforms. The Congressman’s interest in the FDA’s communication with Amazon suggests a concern regarding potential coordination or collusion that may have influenced restrictions placed on NMN sales.
The specified deadline of 11 May, 2023 sets a time frame for the FDA to address Duncan’s concerns and provide the requested information. It remains to be seen how the FDA will respond to the Congressman’s letter and whether a public hearing will be scheduled to address the matter. The outcome of this inquiry could have implications for the dietary supplement industry and the regulations governing the categorization of ingredients like NMN.
